This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
The deal will be Japan’s largest ever corporate takeover and will see Takeda become a leading global pharmaceutical company with combined revenues exceeding $30 billion.
‘We are delighted that our shareholders have given their strong support to our acquisition of Shire,’ said Christophe Weber, President and CEO of Takeda.
‘With shareholder approval secured, we are looking forward to closing the acquisition in the coming weeks to create a more competitive, agile, highly profitable, and therefore more resilient company, poised to deliver highly innovative medicines and transformative care to patients around the world.’
Takeda rises to become global drug maker
Now that the deal has gained approval from Takeda’s shareholders, the acquisition is expected to be finalised next year on 8 January.
The deal is a massive step forward for the Japanese drug marker that will take Takeda from a strong regional player in the Asia to one with a global presence, particularly in the US, which represents the largest pharmaceutical market in the world.
‘Takeda is undergoing a fundamental transformation, from a sleepy regional player to a global player,’ CLSA analyst Stephen Barker wrote in a recent report. ‘Scale is vital because development costs are rising and a global footprint is the key to maximising revenue from new products.’
Shire deal poses big risk for Takeda
Despite a lot of synergies from the Shire deal, the Japanese drug maker is putting down a big bet that it hopes will pay off in the end.
The £46 billion price tag for Shire is massive, with Takeda rumoured to be funding the deal via a mix of new shares and debt, with the Japanese drug maker funding around £25 billion via a rights issue and around £24 billion in bank loans.
The sheer amount of capital raised to go ahead with the acquisition is a cause for concern for investors, which has precipitated in the drug maker’s stock price losing around 20% of its value since the deal was announced.
Investors have become increasingly worried about the dilution risk for existing shareholders and the realisation of how much is at stake if the deal isn’t a success.